Scientific Title:

Safety and Tolerability of Sho-saiko-to (SST) in Patients with Compensated Cirrhosis Due to Chronic HCV Infection, A Double blinded Phase II Trial

Principal Investigator (ie., Lead Researcher):

Tarek Hassanein, MD

Description:

The purpose of this study is to evaluate the safety and tolerability of an investigational drug called Sho-saiko-to (SST) as well as find out more about preventing a type of liver cancer called Hepatocellular Carcinoma (HCC) from occuring in patients who have Chronic Hepatitis C infection and cirrhosis. SST is a Chinese herbal drug mixture of seven different herbs: Bupleurum Root, Pinellia, Ginger, Scutellaria, Jujube, Ginseng and Licorice.

This is an outpatient study.

Gender: Both males and females are eligible to participate. Minimum age: 18. Hepatitis C Virus and Cirrhosis

Exclusions (conditions which would prevent a volunteer from participating in this study):

Please contact Fatma Barakat

Location:

UCSD Medical Center, Hillcrest

Compensation:

Study drug will be provided at no cost.

For further information about this study, please contact:

Fatma Barakat

Phone:

(619) 543-5459

Last update: 02/12/2005